Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): An open-label, randomised phase 3 trial

André Robidoux, Gong Tang, Priya Rastogi, Charles E. Geyer, Catherine A. Azar, James N. Atkins, Louis Fehrenbacher, Harry D. Bear, Louis Baez-Diaz, Shakir Sarwar, Richard G. Margolese, William B. Farrar, Adam M. Brufsky, Henry R. Shibata, Hanna Bandos, Soonmyung Paik, Joseph P. Costantino, Sandra M. Swain, Eleftherios P. Mamounas, Norman Wolmark

Research output: Contribution to journalArticlepeer-review

236 Scopus citations

Fingerprint

Dive into the research topics of 'Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): An open-label, randomised phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences